Spero Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Spero Therapeutics

30/03/2023 22:55

* Spero Therapeutics Inc  SPRO.OQ  reported quarterly
adjusted
earnings of 55 cents​​ per share for the quarter ended in
December. The mean expectation of three analysts for the quarter
was for earnings of 4 cents per share.
    * Revenue rose 1,628.9% to $47.44 million from a year ago;
analysts expected $22.87 million. 
    * Spero Therapeutics Inc's reported EPS for the quarter was
55
cents​.
    * The mean earnings estimate of analysts had fallen by
about 83.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Spero Therapeutics Inc shares had fallen by 16.2% this
quarter.
    * The company reported quarterly net income of $26.77
million.
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 30 at 09:55 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      0.04           0.55           Beat
 Sep. 30 2022      -0.30          -0.33          Missed
 Jun. 30 2022      -0.93          -0.87          Beat
 Mar. 31 2022      -0.87          -1.01          Missed